Literature DB >> 10216220

Antibodies against the extracellular domain of the 5-HT3 receptor label both native and recombinant receptors.

A D Spier1, G Wotherspoon, S V Nayak, R A Nichols, J V Priestley, S C Lummis.   

Abstract

We have developed polyclonal antibodies (pAb120) against a peptide corresponding to a region within the extracellular domain of the 5-hydroxytryptamine3 (5-HT3) receptor subunit, thus permitting, for the first time, localization of 5-HT3 receptors at the cell surface in intact (non-permeabilized) systems. The antibodies are both specific and sensitive: pAb120 recognized as little as 63 ng of protein from HEK293 cells expressing recombinant 5-HT3 receptors, whilst Western blots of recombinant 5-HT3 receptors purified from Sf9 cells revealed two bands at 48 and 54 kDa, and native 5-HT3 receptors from N1E-115 cell membranes produced a broad band at 50-54 kDa with a smaller band at 35 kDa. These bands were also labelled by antibodies against the intracellular loop of the 5-HT3 receptor. Immunofluorescent labelling revealed a ring of intense fluorescence in the plasma membrane of non-permeabilized HEK293 cells expressing recombinant 5-HT3 receptors. Studies on native 5-HT3 receptors revealed that pAb120 could recognize 5-HT3 receptors on presynaptic terminals isolated from rat striatum, and immunohistochemical studies in rat brain sections revealed labelling of cell bodies, dendrites and varicose axons in hippocampus, cortex and lateral hypothalamus; all of these areas have been reported to express 5-HT3 receptors. We conclude that pAb120 is a highly specific and sensitive antiserum that will assist in clarifying fundamental questions about 5-HT3 receptor neurobiology. Copyright 1999 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10216220     DOI: 10.1016/s0169-328x(99)00055-8

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  19 in total

1.  Immunological characterization of 5-HT3 receptor transmembrane topology.

Authors:  Avron D Spier; Sarah C R Lummis
Journal:  J Mol Neurosci       Date:  2002-06       Impact factor: 3.444

2.  Agonists and antagonists bind to an A-A interface in the heteromeric 5-HT3AB receptor.

Authors:  M Lochner; S C R Lummis
Journal:  Biophys J       Date:  2010-04-21       Impact factor: 4.033

3.  Characterization of 5-HT3 receptor mutations identified in schizophrenic patients.

Authors:  Andrew J Thompson; Nora L Sullivan; Sarah C R Lummis
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

4.  A single ring of charged amino acids at one end of the pore can control ion selectivity in the 5-HT3 receptor.

Authors:  Andrew J Thompson; Sarah C R Lummis
Journal:  Br J Pharmacol       Date:  2003-08-11       Impact factor: 8.739

5.  Excitation of rat colonic afferent fibres by 5-HT(3) receptors.

Authors:  Gareth A Hicks; Jonathan R Coldwell; Marcus Schindler; Philip A Bland Ward; David Jenkins; Penny A Lynn; Patrick P A Humphrey; L Ashley Blackshaw
Journal:  J Physiol       Date:  2002-11-01       Impact factor: 5.182

6.  Mapping spatial relationships between residues in the ligand-binding domain of the 5-HT3 receptor using a molecular ruler.

Authors:  Heather L Nyce; Spencer T Stober; Cameron F Abrams; Michael M White
Journal:  Biophys J       Date:  2010-05-19       Impact factor: 4.033

7.  Defining the roles of Asn-128, Glu-129 and Phe-130 in loop A of the 5-HT3 receptor.

Authors:  Nora L Sullivan; Andrew J Thompson; Kerry L Price; Sarah C R Lummis
Journal:  Mol Membr Biol       Date:  2006 Sep-Oct       Impact factor: 2.857

Review 8.  5-HT3 receptors.

Authors:  A J Thompson; S C R Lummis
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

9.  Calcium modulation of 5-HT3 receptor binding and function.

Authors:  Andrew J Thompson; Sarah C R Lummis
Journal:  Neuropharmacology       Date:  2008-07-16       Impact factor: 5.250

Review 10.  The 5-HT3 receptor--the relationship between structure and function.

Authors:  Nicholas M Barnes; Tim G Hales; Sarah C R Lummis; John A Peters
Journal:  Neuropharmacology       Date:  2008-08-12       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.